# Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

> **NCT01278342** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Sandostatin LAR
- **DRUG:** pegvisomant
- **DRUG:** cabergoline

## Key facts

- **NCT ID:** NCT01278342
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278342, "Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01278342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*